Trial reportClinical infectious diseases : an official publication of the Infectious Diseases Society of America2016
Cysticidal Efficacy of Combined Treatment With Praziquantel and Albendazole for Parenchymal Brain Cysticercosis.
Trial report in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00441285 (Antiparasitic Therapy for Neurocysticercosis), which is not on this map. Cited by 33 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Antiparasitic Therapy for Neurocysticercosis: Phase II/III Study on Safety and Efficacy of Combined Treatment With Praziquantel and Albendazole
Who cites it
33 citing papers in PubMed, 2 syntheses or guidelines pooled it, 78 citations in OpenAlex.
- Diagnosis and Treatment of Neurocysticercosis: 2017 Clinical Practice Guidelines by the Infectious Diseases Society of America (IDSA) and the American Society of Tropical Medicine and Hygiene (ASTMH).Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2018Guideline
- Diagnosis and Treatment of Neurocysticercosis: 2017 Clinical Practice Guidelines by the Infectious Diseases Society of America (IDSA) and the American Society of Tropical Medicine and Hygiene (ASTMH).The American journal of tropical medicine and hygiene · 2018Guideline
- Taenia solium neurocysticercosis: Its current epidemiological, diagnostic, therapeutic, and control landscapes.PLoS neglected tropical diseases · 2026Review
- Calcified Neurocysticercosis: Understanding Dead (Not Necessarily Inactive) Parasites.The American journal of tropical medicine and hygiene · 2025Review
- Analytical Method for the Simultaneous Determination of Albendazole and Metabolites Using HPLC-PDA: A Validation Study.Molecules (Basel, Switzerland) · 2025Article
- A case report of disseminated cysticercosis in Guangxi Zhuang Autonomous Region, Southwest China.BMC infectious diseases · 2024Article
- Paragonimiasis misdiagnosed as liver abscess: A case report.World journal of clinical cases · 2024Article
- Increased Prevalence of Antibodies to Hepatitis E Virus in Patients with Neurocysticercosis.The American journal of tropical medicine and hygiene · 2024Article
- Albendazole and praziquantel combination versus albendazole alone in children with multiple neurocysticercosis: An open labelled randomized controlled trial.Journal of family medicine and primary care · 2024Article
- Unmasking a Hidden Culprit: Neurocysticercosis, an Overlooked Cause of Acquired Epilepsy.Journal of epilepsy research · 2024Article
- Can sPD-1 and sPD-L1 Plasma Concentrations Predict Treatment Response among Patients with Extraparenchymal Neurocysticercosis?Pathogens (Basel, Switzerland) · 2023Article
- Efficacy and safety of antiparasitic therapy for neurocysticercosis in rural Tanzania: a prospective cohort study.Infection · 2023Article
- Disseminated Human Subarachnoid Coenurosis.Tropical medicine and infectious disease · 2022Article
- Human Neurocysticercosis: An Overview.Pathogens (Basel, Switzerland) · 2022Review
- Update on the diagnosis and management of neurocysticercosis.Arquivos de neuro-psiquiatria · 2022Review
- Neurocysticercosis: A Review into Treatment Options, Indications, and Their Efficacy.Research and reports in tropical medicine · 2022Review
- Frequency and Determinant Factors for Calcification in Neurocysticercosis.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2021Article
- Parasitic Infections of the Nervous System.Continuum (Minneapolis, Minn.) · 2021Review
- Mortality in Parenchymal and Subarachnoid Neurocysticercosis.The American journal of tropical medicine and hygiene · 2021Article
- Taenia solium Cysticercosis and Its Impact in Neurological Disease.Clinical microbiology reviews · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 6 institutions in 3 countries.
Funding
Abstract
backgroundThe efficacy of current antiparasitic treatment for cerebral Taenia solium cysticercosis with either albendazole (ABZ) or praziquantel (PZQ) is suboptimal. A recent study demonstrated that combining these 2 antiparasitic drugs improves antiparasitic efficacy. We present here the parasiticidal efficacy data obtained during a previous phase II pharmacokinetic study that compared combined ABZ plus PZQ with ABZ alone.
methodsThe study was a randomized, double-blinded, placebo-controlled phase II evaluation of the pharmacokinetics of ABZ (15 mg/k/d, for 10 days) and PZQ (50 mg/k/d, for 10 days) in intraparenchymal brain cysticercosis. Patients received the usual concomitant medications, including an antiepileptic drug (phenytoin or carbamazepine), dexamethasone, and ranitidine. Randomization was stratified by antiepileptic drug. Patients underwent safety laboratory evaluations at days 4, 7, and 11, as well as magnetic resonance (MR) imaging at 6 months to assess parasiticidal efficacy.
resultsThirty-two patients were included, 16 in each arm. All of them completed antiparasitic treatment and underwent follow-up brain MR imaging. Cysticidal efficacy was strikingly higher in the combined ABZ-plus-PZQ group than in the ABZ-alone group (proportion of cysts resolved, 78 of 82 [95%] vs 23 of 77 [30%] [relative risk {RR}, 3.18; 95% confidence interval {CI}, 2.08-4.88; P < .001]; patients with complete cyst clearance, 12 of 16 [75%] vs 4 of 16 [25%] [RR, 3.00; 95% CI, 1.23-7.34; P = .005]).
conclusionsThe combination of ABZ plus PZQ is more effective in destroying viable brain cysticercosis cysts than ABZ alone. CLINICAL TRIALS REGISTRATION: NCT00441285.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.